“We thoroughly surveyed the market and selected what we think is the leading antibody R&D workflow platform.” -Dr. Bjoern Hock, Global Head Protein Engineering and Antibody Technologies at Merck Serono.
Basel, Switzerland (PRWEB) July 22, 2015
Genedata, a leading provider of advanced software solutions for drug discovery and life science research, today announced that Merck Serono, the biopharma business of Merck, Darmstadt, Germany, has adopted Genedata Biologics™ as their central workflow platform at biopharma R&D units, which include R&D sites in Germany, Israel, and the US, where the company is called EMD Serono. Using Genedata Biologics, Merck Serono will streamline its large-molecule research processes to increase both productivity and quality.
“We thoroughly surveyed the market and selected what we think is the leading antibody R&D workflow platform,” said Dr. Bjoern Hock, Director, Global Head Protein Engineering and Antibody Technologies at Merck Serono. “The platform will help to increase Merck Serono’s throughput in antibody screening, engineering, and expression. Genedata Biologics will be our central repository for mission-critical data on therapeutic candidates such as bioactivity, developability, and manufacturability, and will enable transparent decision-making on candidates to move forward with.”
The platform addresses Merck Serono’s proprietary workflows and technologies, such as their high-throughput B-cell screening platform, protein engineering workflows for novel next-generation antibody formats, and novel library technologies. The system will be deployed across different biopharma research centers and will harmonize all biologics discovery processes, including molecular biology, expression, purification, and analytics processes. It will be fully integrated into Merck Serono’s IT landscape and laboratory infrastructure.
“We are rapidly expanding our biotherapeutic R&D activities and needed a scalable, flexible platform that we could quickly and easily implement. We chose Genedata Biologics as it is the only out-of-the-box platform on the market dedicated to large-molecule R&D,” said Dr. Veit Ulshöfer, Director, Global Head of Research and Bioinformatics at Merck. “Genedata Biologics will serve as our central system for registering, processing, interpreting, and sharing all our large-molecule data.”
“We are very pleased that Merck Serono, a major player in developing innovative protein therapeutics, has decided to implement Genedata Biologics as their corporate infrastructure for large-molecule research,” said Dr. Othmar Pfannes, CEO of Genedata. “This new collaboration validates our strategy of offering a complete enterprise product platform tailored for biopharma R&D. Our platform reduces costs, increases research efficiency, and provides a clear path for adopting new processes in this quickly evolving field, while keeping IT costs under control and deployment times at a minimum. We are committed to further expanding the platform in close collaboration with our rapidly growing customer base to support new workflows and applications.”
In the four short years since its first release in 2011, Genedata Biologics has been rapidly adopted by almost half of the world’s leading biopharmaceutical companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.
Genedata transforms data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the US.
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.